CLL high-risk genetics (TP53 / del(17p) / IGHV-unmutated / complex karyotype)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`BIO-CLL-HIGH-RISK-GENETICS`
Type	Biomarker
Aliases	CLL high-risk genetics compositeЦитогенетика високого ризику при ХЛЛ (TP53/del(17p)/IGHV-unmutated/комплексний каріотип)
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-BCELL-2025`

Biomarker Facts

Biomarker type	composite_score
Measurement	MethodFISH for del(17p), TP53 sequencing, IGHV mutational analysis, karyotype on stimulated PBMC Unitscategorical (high-risk \| standard-risk)
Related biomarkers	`BIO-TP53-MUTATION` `BIO-IGHV-MUTATIONAL-STATUS` `BIO-NOTCH1-MUTATION`

Notes

Composite "high-risk" if ANY: TP53 mutation OR del(17p) OR IGHV-unmutated (germline ≥98% homology). Complex karyotype (≥3 abnormalities) compounds risk further. Drives 1L preference toward fixed-duration venetoclax+obinutuzumab over BTKi in some guidelines (CLL14 trial — high-risk subgroup similar PFS). Refractory chemoimmuno with high-risk → AVOID FCR/BR; go BTKi or venetoclax-O.

Used By

Biomarker

BIO-IGHV-MUTATIONAL-STATUS - IGHV (immunoglobulin heavy-chain variable region) mutational status
BIO-SF3B1 - SF3B1 mutation
BIO-TP53-MUTATION - TP53 mutation / del(17p)

Questionnaires

QUEST-CLL-1L - Chronic Lymphocytic Leukemia / SLL — first line

Red flag

RF-CLL-HIGH-RISK - CLL with high-risk genetics: TP53 mutation OR del(17p) OR IGHV-unmutated OR complex karyo...